PHILADELPHIA, Oct. 8, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the “Company”), announced that Dr. H. Hasegawa, Chief, Laboratory of Mucosal Vaccine Development Virus Research Center, Japanese National Institute of Infectious Diseases (JIID), will review data on Ampligen(R), an experimental immunotherapeutic, at the “Mucosal Immunity” session of the Japan-France Vaccine and Infectious Diseases Workshop in Osaka, October 10, 2009. (Please see http://www.osaka-u.ac.jp/en/seminar/info/2009/10/594) Dr. Hasegawa is the Principal Investigator on the Ampligen(R)/ Influenza vaccine program under the joint auspices of JIID/ Ministry of Health, Biken Corporation (Osaka) and Hemispherx Biopharma. Dr. Hasegawa will provide an overview of intranasal pandemic flu vaccine and nasal immunity mechanisms.
